Search
Rifalazil
go.drugbank.com/drugs/DB04934InvestigationalRifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigationalLofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTipifarnib
go.drugbank.com/drugs/DB04960InvestigationalTipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. ...
Categories: P-glycoprotein inhibitorsGanaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigationalGanaxolone is the 3β-methylated synthetic analog of allopregnanolone, a metabolite of progesterone. Ganaxolone belongs to a class of compounds referred to as neurosteroids. Endogenous neurosteroids, which comprise certain metabolites of ...
Categories: Cytochrome P-450 Substrates, Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive ModulatorTrabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalTrabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSQ-109
go.drugbank.com/drugs/DB05186InvestigationalSQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTelaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnTelaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLaromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 SubstratesSar9, Met (O2)11-Substance P
go.drugbank.com/drugs/DB05875InvestigationalSar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. … It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.
Synonyms: 9-Sar-substance P sulfone, 9-Sar-11-met(O2)-substance P